ReviewAdvanced drug delivery reviews2021
Advanced human-relevant in vitro pulmonary platforms for respiratory therapeutics.
Review in Advanced drug delivery reviews, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Balancing stability and cellular interaction in surface-engineered small extracellular vesicles for pulmonary delivery.Materials today. Bio · 2026Article
- Review
- iPSC-Derived Bronchial Airways-On-Chip for the Assessment of Cytokine Secretion Triggered by Volatile Organic Compounds.ACS biomaterials science & engineering · 2026Article
- In Vitro Evaluation of the Effect of Size and PEGylation on Inhalable Liposomes for Pulmonary Drug Delivery.Nanomaterials (Basel, Switzerland) · 2026Article
- Impact of physiological strain on lung epithelial cells by exposure to aerosolised quartz silica in a perfused bioreactor.Frontiers in bioengineering and biotechnology · 2026Article
- Simple-Flow: A 3D-Printed Multiwell Flow Plate to Coculture Primary Human Lung Cells at the Air-Liquid Interface.ACS biomaterials science & engineering · 2025Article
- A 3D Model of the Human Lung Airway for Evaluating Permeability of Inhaled Drugs.ACS pharmacology & translational science · 2025Article
- Advanced pathophysiology mimicking lung models for accelerated drug discovery.Biomaterials research · 2023Article
- Understanding fibroblast-immune cell interactionsFrontiers in immunology · 2023Review
- A multiplex inhalation platform to modelFrontiers in pharmacology · 2023Article
- Ventilation-induced epithelial injury drives biological onset of lung trauma in vitro and is mitigated with prophylactic anti-inflammatory therapeutics.Bioengineering & translational medicine · 2022Article
- Human Multi-CompartmentFrontiers in physiology · 2022Article
- AnFrontiers in bioengineering and biotechnology · 2022Article
- Investigation of the role of the autophagic protein LC3B in the regulation of human airway epithelium cell differentiation in COPD using a biomimetic model.Materials today. Bio · 2022Article
- Editorial: InnovativeFrontiers in bioengineering and biotechnology · 2021Article
- Efficacy of β-agonists in prevention and treatment of acute lung injury: A meta-analysis of randomized controlled trials.Annals of thoracic medicineReview
- Advanced lung organoids for respiratory system and pulmonary disease modeling.Journal of tissue engineeringReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Over the past years, advanced in vitro pulmonary platforms have witnessed exciting developments that are pushing beyond traditional preclinical cell culture methods. Here, we discuss ongoing efforts in bridging the gap between in vivo and in vitro interfaces and identify some of the bioengineering challenges that lie ahead in delivering new generations of human-relevant in vitro pulmonary platforms. Notably, in vitro strategies using foremost lung-on-chips and biocompatible "soft" membranes have focused on platforms that emphasize phenotypical endpoints recapitulating key physiological and cellular functions. We review some of the most recent in vitro studies underlining seminal therapeutic screens and translational applications and open our discussion to promising avenues of pulmonary therapeutic exploration focusing on liposomes. Undeniably, there still remains a recognized trade-off between the physiological and biological complexity of these in vitro lung models and their ability to deliver assays with throughput capabilities. The upcoming years are thus anticipated to see further developments in broadening the applicability of such in vitro systems and accelerating therapeutic exploration for drug discovery and translational medicine in treating respiratory disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.